GeneDx (NASDAQ:WGS) CFO Sells $68,072.82 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,266 shares of the business’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $53.77, for a total value of $68,072.82. Following the completion of the sale, the chief financial officer directly owned 36,486 shares of the company’s stock, valued at $1,961,852.22. The trade was a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, April 29th, Kevin Feeley sold 392 shares of GeneDx stock. The shares were sold at an average price of $65.19, for a total value of $25,554.48.
• On Monday, March 16th, Kevin Feeley sold 5,706 shares of GeneDx stock. The shares were sold at an average price of $76.80, for a total value of $438,220.80.

GeneDx Stock Down 1.8%

GeneDx stock opened at $59.92 on Friday. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The company has a market capitalization of $1.78 billion, a P/E ratio of -22.36 and a beta of 1.96. The stock has a 50-day simple moving average of $54.95 and a 200-day simple moving average of $90.19.

GeneDx (NASDAQ:WGS) last posted its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The firm had revenue of $102.25 million during the quarter, compared to analysts’ expectations of $112.46 million. During the same period in the previous year, the firm posted ($0.23) earnings per share. Equities research analysts expect that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Hedge fund manager Eli Casdin is reportedly adding to his GeneDx position, which may be seen as a sign that some sophisticated investors still view the stock as undervalued. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Several law firms continue to remind investors about the pending securities class action and the August 3 lead-plaintiff deadline. These notices keep the lawsuit in focus, but do not add new operational developments. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional legal updates from Rosen, Faruqi & Faruqi, Schall, Robbins, and others reinforce the litigation backdrop tied to GeneDx’s Fabric Genomics acquisition and the Q1 2026 selloff. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares this week. The company says the sales were for tax withholding tied to vesting equity awards, but insider selling can still weigh on sentiment. CEO Form 4 Filing
• Negative Sentiment: The biggest overhang remains the securities class action alleging GeneDx misled investors about reimbursement rates, margin pressure, and the impact of the Fabric Genomics acquisition after a major stock drop and write-off tied to the deal. GeneDx Holdings (WGS) Faces Securities Class Action…

Institutional Trading of GeneDx

Several institutional investors and hedge funds have recently added to or reduced their stakes in WGS. Goldman Sachs Group Inc. increased its position in GeneDx by 4.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after purchasing an additional 52,322 shares during the period. Vanguard Group Inc. increased its position in GeneDx by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock worth $154,650,000 after purchasing an additional 18,647 shares during the period. Franklin Resources Inc. increased its position in GeneDx by 60.4% during the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after purchasing an additional 411,607 shares during the period. Westfield Capital Management Co. LP increased its position in GeneDx by 87.1% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after purchasing an additional 474,167 shares during the period. Finally, Invesco Ltd. increased its position in GeneDx by 59.2% during the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after purchasing an additional 292,394 shares during the period. 61.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on WGS shares. Jefferies Financial Group set a $150.00 price objective on GeneDx in a research note on Monday, February 23rd. Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Guggenheim reduced their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 24th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $85.00 price objective on shares of GeneDx in a research note on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, GeneDx currently has an average rating of “Moderate Buy” and a consensus price target of $96.43.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.